Cytokines, Chemokines & Receptors

Cat. No.

AT0024

CAS No.

879293-15-9

Ordesekimab

Synonyms: AMG 714; PRV-015

Ordesekimab is a fully human IgG1κ monoclonal antibody that targets interleukin-15 (IL-15). It blocks the interaction of IL-15 with the IL-2Rβ and common γ chain components of the IL-15 receptor complex, without affecting binding to IL-15Rα. Ordesekimab is a valuable tool for studying IL-15–driven immune responses and is under investigation for use in nonresponsive celiac disease (NRCD).

Cat. No.

AT0073

CAS No.

2923284-76-6

Lecankitug

Lecankitug is a humanized monoclonal antibody engineered to selectively target and neutralize both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). By binding to these cytokines, Lecankitug effectively inhibits their signal transduction pathways, resulting in pronounced immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into the pathogenesis and potential treatment strategies for autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis.

Cat. No.

AT0090

CAS No.

1044515-88-9

Tralokinumab

Synonyms: CAT354

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

Cat. No.

AT0111

CAS No.

2428381-52-4

Gumokimab

Synonyms: AK 111

Gumokimab (AK 111) is a monoclonal antibody specifically designed to target IL-17A. This antibody effectively inhibits the interaction between IL-17A and its receptor, IL-17R, through competitive binding. It is primarily utilized in research focused on inflammatory conditions such as psoriasis and ankylosing spondylitis, offering a valuable tool for the investigation of the pathophysiological roles of IL-17A in these diseases.

Cat. No.

AT0147

CAS No.

1236278-28-6

Clazakizumab

Clazakizumab is a monoclonal antibody designed to target and neutralize interleukin-6 (IL-6), a cytokine implicated in a wide array of inflammatory responses. This antibody exhibits high affinity and specificity for IL-6, making it a valuable tool in the study of cytokine-mediated processes. Clazakizumab has potential applications in the inhibition of the cytokine storm associated with SARS-CoV-2 infection in COVID-19 patients. Additionally, it is utilized in research focused on psoriatic arthritis (PsA) and renal antibody-mediated rejection, providing insights into the therapeutic mechanisms and potential clinical applications in these conditions.

Cat. No.

AT0176

CAS No.

2556646-63-8

Visugromab

Synonyms: CTL-002

Visugromab (CTL-002) is an IgG4 monoclonal antibody designed to neutralize Growth Differentiation Factor 15 (GDF-15). This antibody has demonstrated synergistic anticancer effects when used in combination with the anti-PD1 antibody Nivolumab. It is particularly effective in treating PD-1/PD-L1 relapsed or refractory metastatic solid tumors, offering a promising therapeutic option for advanced cancer management.

Cat. No.

AT0182

CAS No.

331731-18-1

Adalimumab

Synonyms: Anti-Human TNF-alpha; Human Antibody

Adalimumab is a recombinant human monoclonal IgG1 antibody that specifically targets and neutralizes tumor necrosis factor alpha (TNF-α). This interaction inhibits the inflammatory response associated with autoimmune diseases, making Adalimumab essential for research in immunology and inflammation.

Cat. No.

AT0233

CAS No.

375823-41-9

Tocilizumab

Synonyms: Anti-Human IL6R; Humanized Antibody

Tocilizumab, a humanized monoclonal antibody, targets and neutralizes the interleukin-6 receptor (IL-6R). By blocking the interaction of IL-6 with IL-6R, Tocilizumab effectively inhibits both classical and trans-signaling pathways. This antibody is primarily utilized in the therapeutic management of rheumatoid arthritis, leveraging its ability to modulate inflammatory responses. Additionally, Tocilizumab has demonstrated significant efficacy in research focused on severe cases of COVID-19, highlighting its potential in addressing cytokine release syndrome and related complications. This makes it a valuable tool for both clinical and research applications in immune-mediated inflammatory disorders.

Cat. No.

AT0247

CAS No.

1326232-46-5

Anifrolumab

Anifrolumab is a human monoclonal antibody that functions as a type I interferon (IFN) receptor antagonist. By blocking the activity of type I interferons, Anifrolumab serves as a critical tool in the study of systemic lupus erythematosus (SLE). This antibody provides a valuable means for researchers to explore the role of type I IFN in the pathogenesis and potential therapeutic targeting of SLE.

Cat. No.

AT0260

CAS No.

2643349-04-4

Varokibart

Varokibart (TEV-53275) is a humanized IgG4λ monoclonal antibody designed to specifically target and neutralize interleukin 5 (IL-5). This antibody is engineered for stability and reduced immunogenicity, making it an ideal tool for research focused on the role of IL-5 in eosinophilic disorders and other inflammatory conditions.

Cat. No.

AT0295

CAS No.

476181-74-5

Golimumab

Synonyms: CNTO-148

Golimumab (CNTO-148) is a potent monoclonal antibody of the human IgG1 subclass that functions as a TNFα antagonist. It exhibits anti-inflammatory properties by inhibiting the production of interleukins IL-6 and IL-1β. The mechanism of action of Golimumab involves targeting and neutralizing tumor necrosis factor (TNF), thereby preventing inflammation and the associated degradation of cartilage and bone. Additionally, Golimumab demonstrates anticancer properties through the induction of cell apoptosis. This antibody is applicable in the research of rheumatoid arthritis, Crohn's disease, and various cancers, providing a valuable tool for both basic research and therapeutic development.

Cat. No.

AT0345

CAS No.

946414-98-8

Eldelumab

Synonyms: BMS-936557; MDX-1100

Eldelumab (BMS-936557) is a human monoclonal antibody of the IgG1 subtype designed to selectively target and neutralize CXCL10 (IP-10). By binding to CXCL10, Eldelumab effectively inhibits CXCL10-induced calcium flux and cellular migration. This antibody is particularly useful in research focused on autoimmune and auto-inflammatory disorders, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease, providing a valuable tool for elucidating the role of CXCL10 in these conditions.

Cat. No.

AT0384

CAS No.

2043952-59-4

Abrezekimab

Synonyms: UCB4144; VR 942

Abrezekimab (VR 942), featuring CDP7766, is a humanized, high-affinity monoclonal antibody fragment with neutralizing properties against human interleukin-13 (IL-13). It specifically binds to IL-13, effectively preventing interaction with the IL-13Rα1 receptor subunit. This antibody is primarily utilized in asthma research to investigate the role and therapeutic potential of IL-13 inhibition in disease pathogenesis and progression.

Cat. No.

AT0394

CAS No.

953400-68-5

Lebrikizumab

Synonyms: TNX-650

Lebrikizumab (TNX-650) is a humanized IgG4 monoclonal antibody that targets interleukin-13 (IL-13), binding specifically to a non-receptor binding domain of IL-13 to inhibit its activity. This antibody effectively blocks the IL-13-driven Th2 inflammatory response by interfering with the signaling pathway involving IL-4Rα/IL-13Rα1. Lebrikizumab also exhibits anti-itch properties, making it a valuable tool for research into asthma, atopic dermatitis, and neuroinflammatory disorders.

Cat. No.

AT0421

CAS No.

2492472-82-7

Camoteskimab

Synonyms: AVTX-007; CERC-007; MEDI 2338

Camoteskimab (AVTX-007) is a fully humanized, high-affinity monoclonal antibody targeting interleukin-18 (IL-18). By specifically binding to IL-18, Camoteskimab effectively inhibits the interaction between IL-18 and its receptor, thereby modulating the inflammatory response. This antibody is particularly valuable in research focused on cardiovascular and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma, providing a potent tool for investigating the pathological roles of IL-18 in these conditions.

Cat. No.

AT0427

CAS No.

2084037-83-0

Quetmolimab

Quetmolimab is a humanized monoclonal antibody targeting CX3CL1, a chemokine known for its role in modulating chemotaxis and cell adhesion. This antibody is designed for precision in binding and neutralizing CX3CL1, making it a valuable tool for research into inflammatory responses and immune cell migration.

Cat. No.

AT0504

CAS No.

2649854-92-0

Nisevokitug

Synonyms: NIS-793

Nisevokitug (NIS-793) is a recombinant human IgG2λ monoclonal antibody specifically designed to target and neutralize transforming growth factor-beta (TGF-β), encompassing both TGFB1 and TGFB2 isoforms. This antibody is produced in CHO-K1 cells, ensuring high fidelity and consistency in performance. Nisevokitug is utilized primarily in research focused on the modulation of TGF-β activity, which is crucial in various physiological and pathological processes including cell growth, inflammation, and fibrosis.

Cat. No.

AT0511

CAS No.

1791410-27-9

Remtolumab

Synonyms: ABT-122

Remtolumab (ABT-122) is a dual-variable domain immunoglobulin specifically engineered to neutralize tumor necrosis factor α (TNFα) and interleukin-17A (IL-17A). This biologic exhibits potent dual inhibition, effectively targeting both cytokines implicated in inflammatory processes. It is particularly useful in research focused on rheumatoid arthritis (RA), providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.

Cat. No.

AT0564

CAS No.

1418205-77-2

Bimekizumab

Synonyms: Anti-Human IL17A/IL-17F Recombinant Antibody

Bimekizumab is a humanized monoclonal antibody designed to selectively neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). These cytokines are known to promote osteogenic differentiation in human periosteum-derived cells (hPDCs). By targeting IL-17A and IL-17F, Bimekizumab effectively inhibits the inflammation-driven osteogenic differentiation, making it a valuable tool in research focused on inflammatory processes and bone metabolism.

Cat. No.

AT0632

CAS No.

1589503-30-9

Afasevikumab

Synonyms: RG 7624; RO 5553110; NI-1401

Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1κ antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.

Cat. No.

AT0649

CAS No.

339308-60-0

Briakinumab

Synonyms: ABT-874

Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.

Cat. No.

AT0676

CAS No.

2921564-55-6

Adezkibart

Adezkibart is a human monoclonal antibody developed as an immunosuppressant, specifically targeting the human FMS-like tyrosine kinase 3 ligand (FLT3LG). Produced in the Chinese hamster ovary (CHO) cell line CHO-K1, this antibody binds selectively to FLT3LG, effectively blocking the associated signaling pathway. By inhibiting this pathway, Adezkibart reduces the immune response and demonstrates potent immunosuppressive effects. This antibody is particularly valuable for research into immune-related diseases, offering insights into immune regulation and potential therapeutic targets.

Cat. No.

AT0748

CAS No.

914613-48-2

Canakinumab

Synonyms: Ilaris; ACZ 885

Canakinumab (ACZ885) is a recombinant human monoclonal antibody that specifically targets and neutralizes interleukin-1 beta (IL-1β). Demonstrating potent inhibitory activity, canakinumab exhibits half-maximal inhibitory concentrations (IC50) of 43.6 pM for human IL-1β and 40.8 pM for marmoset IL-1β. Its primary mechanism involves the interruption of IL-1β signaling, effectively reducing inflammatory responses associated with autoimmune disorders. This antibody is pivotal for research focused on the pathophysiology and potential therapeutic interventions for inflammation-driven diseases.

Cat. No.

AT0767

CAS No.

1365659-05-7

Atrosab

Atrosab is a humanized IgG1 monoclonal antibody that functions as an antagonist to tumor necrosis factor receptor 1 (TNFR1). It effectively inhibits TNF-alpha-mediated apoptosis and the production of interleukins IL-6 and IL-8, key mediators in inflammatory processes. This antibody has been shown to reduce neurological deficits, highlighting its potential utility in the study of neuroinflammation and other inflammatory diseases. For control experiments, the recommended isotype control is Human IgG1 kappa.

Cat. No.

AT0819

CAS No.

2744320-12-3

Vamikibart

Vamikibart is a chimeric humanized monoclonal antibody of the IgG2κ isotype, specifically designed to target interleukin 6 (IL-6). This antibody is engineered for high specificity and affinity in neutralizing IL-6, a cytokine involved in various inflammatory and autoimmune processes. Vamikibart is suitable for use in research focused on the role of IL-6 in disease mechanisms and therapeutic interventions.